Drug intelligence / Profile preview

necrostatin-1S

Development stage
Unknown
Modality
Small Molecules
Administration
Intraperitoneal, Intravenous
01

Overview

Necrostatin-1S (Nec-1s) is a potent, highly selective, and metabolically stable small-molecule allosteric inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). Developed as an optimized analog of necrostatin-1 (Nec-1), Nec-1s lacks the off-target inhibitory activity against indoleamine 2,3-dioxygenase (IDO) that is characteristic of its predecessor, while exhibiting approximately two-fold greater potency in blocking RIPK1-mediated necroptosis. It binds to the allosteric pocket of the RIPK1 kinase domain, preventing its autophosphorylation and subsequent activation of the RIPK3-MLKL signaling cascade. Nec-1s is widely utilized as a chemical probe in preclinical research to investigate the role of necroptosis and RIPK1-dependent inflammation in various pathological conditions, including neurodegenerative diseases (such as Alzheimer's disease and amyotrophic lateral sclerosis), ischemia-reperfusion injury, and acute inflammatory disorders.

Other names
7-Cl-O-Nec-17-Cl-O-necrostatin-1Nec-1SNec1SNec 1SNecrostatin-2 racemateNecrostatin2 racemateNecrostatin 2 racemateRIP1 Inhibitor IIRIP-1 Inhibitor IIRIP 1 Inhibitor IInecrostatin-1snecrostatin1snecrostatin 1s
02

Targets

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on necrostatin-1S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on necrostatin-1S.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call